Hoya (HOCPY)
(Delayed Data from OTC)
$117.49 USD
-1.80 (-1.51%)
Updated Apr 25, 2024 03:49 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HOCPY 117.49 -1.80(-1.51%)
Will HOCPY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HOCPY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOCPY
Here's Why Momentum in Hoya Corp. (HOCPY) Should Keep going
Here's What Could Help Hoya Corp. (HOCPY) Maintain Its Recent Price Strength
HOCPY: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Hoya Corp. (HOCPY) a Good Fit for 'Trend Investing'
Here's Why 'Trend' Investors Would Love Betting on Hoya Corp. (HOCPY)
CARR vs. HOCPY: Which Stock Is the Better Value Option?
Other News for HOCPY
Hoya Corp. reinstated with a Buy at Nomura
IN BRIEF: Hoya says business returning to normal after IT system hack
LONDON MARKET CLOSE: Stocks recover some of recent Fed talk losses
AIM WINNERS & LOSERS: Surgical Innovations up as revenue jumps
Surgical Innovations sets sights on future growth after record revenue